TLX News: Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection fo - 4th Oct 2024, 9:00pm

annb0t

Top 20
Telix Pharmaceuticals Limited

MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Health Canada has approved the use of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA1-targeted radionuclide therapy.

The label expansion means that Illuccix is now approved in Canada to select patients with progressive metastatic castration-resistant prostate cancer (m...

>>> Read more: Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
 
Top Bottom